Attovia Therapeutics, Inc. (ATTO) AI Stock Analysis

13 Followers

Attovia Therapeutics, Inc.

(NASDAQ:ATTO)

Select Model

Rating:52Neutral

Price Target:$15.50▼(-6.85% Downside)

Action:reiterated

Date:11/10/26

ATTO scores in the low-to-mid range primarily due to very weak profitability and significant cash burn, partially mitigated by a relatively strong balance sheet. Technical indicators are mixed without clear bullish momentum, while valuation is constrained by losses (negative P/E) and no dividend support. The main upside factor is the positive Phase 1b readout for ATTO-1310 alongside increased cash after the IPO.

Positive Factors

ATTO-1310 clinical efficacyThe positive Phase 1b signal provides clinical validation for ATTO-1310, including meaningful symptom response, biomarker suppression, and favorable tolerability. If sustained in later development, these results could strengthen the program’s partnering potential and support advancement toward a commercial therapy.

Negative Factors

Severe profitability deficitThe wide gap between modest revenue and substantial net loss shows that the current business has not yet developed earnings power. Continued losses can consume the capital base and make future financial performance dependent on successful development and eventual commercialization.

Attovia Therapeutics, Inc. (ATTO) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $759.64M
Dividend Yield: ―
Average Volume (3M): 346.40K
Price to Earnings (P/E): -7.4
Beta (1Y): -0.73
Revenue Growth: ―
EPS Growth: ―
Country: US
Employees: 44
Sector: General
Sector Strength: 55
Industry: Biotechnology

Attovia Therapeutics, Inc. Business Overview & Revenue Model

Company Description

A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the t...

Attovia Therapeutics, Inc. Financial Statement Overview

Summary

Financial performance is weak overall: the income statement reflects extremely large losses (2025 net loss about -$60.6M) on modest revenue ($1.35M), and cash flow shows heavy ongoing cash burn (2025 operating cash flow about -$59.2M; free cash flow about -$61.5M). Offsetting this, the balance sheet is comparatively supportive with high equity (~$150.8M) and low debt (~$5.3M), providing near-term flexibility despite negative returns.

Income Statement

18Very Negative

Balance Sheet

62Positive

Cash Flow

24Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	450.00K	1.35M	0	1.45B	1.41B	1.71B
Gross Profit	-38.00K	546.00K	-313.00K	1.36B	1.34B	1.64B
EBITDA	-66.29M	-66.36M	-41.24M	232.70M	176.90M	204.40M
Net Income	-61.61M	-60.63M	-39.80M	-90.20M	-46.80M	-80.70M
Balance Sheet
Total Assets	411.82M	165.89M	76.72M	1.10B	1.19B	1.32B
Cash, Cash Equivalents and Short-Term Investments	395.94M	152.27M	69.32M	129.57M	210.15M	125.80M
Total Debt	3.84M	5.26M	0	718.28M	726.58M	720.61M
Total Liabilities	14.08M	15.10M	14.59M	1.11B	1.07B	1.12B
Stockholders Equity	397.74M	150.79M	62.13M	-10.19M	119.09M	207.02M
Cash Flow
Free Cash Flow	-60.98M	-61.51M	-36.81M	-5.80M	90.00M	6.30M
Operating Cash Flow	-60.60M	-59.20M	-35.03M	42.30M	128.20M	46.40M
Investing Cash Flow	-170.38M	-73.45M	-39.80M	-50.50M	-38.20M	-56.00M
Financing Cash Flow	306.16M	142.01M	82.75M	-58.20M	-300.00K	5.10M

Attovia Therapeutics, Inc. Risk Analysis

Attovia Therapeutics, Inc. disclosed 89 risk factors in its most recent earnings report. Attovia Therapeutics, Inc. reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks

1.Accordingly,investorsmay only realizefuture gainson theirinvestmentsif the price oftheir ordinaryshares increases.Q4, 2021

2.Futureequity issuancesmaydilutethe holdingsof ordinaryshareholdersandcould materiallyaffectthe marketprice ofQ4, 2021

3.judgments againstus or ourexecutive officersand directors inthe UnitedStates.Q4, 2021

Attovia Therapeutics, Inc. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

ATTO against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ANAB	66Neutral	$1.45B	7.17	2515.23%	―	92.92%	―
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
MLTX	52Neutral	$1.07B	-3.41	-79.95%	―	―	-10.20%
ATTO	52Neutral	$760.66M	-7.39	-35.47%	―	―	―
EVMN	47Neutral	$284.53M	-2.33	-62.63%	―	―	―
ALMS	41Neutral	$854.37M	-1.68	-102.97%	―	-63.11%	15.36%
ZURA	40Underperform	$135.34M	-1.25	-53.97%	―	―	-76.37%

* General Sector Average

Performance Comparison

ATTO and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
ATTO	Attovia Therapeutics, Inc.	16.64	-5.26	-24.02%
ANAB	AnaptysBio	48.38	26.32	119.35%
MLTX	Moonlake Immunotherapeutics	12.56	-0.21	-1.64%
ZURA	Zura Bio Limited	1.41	-3.22	-69.65%
ALMS	Alumis Inc.	6.40	1.16	22.14%
EVMN	Evommune, Inc.	7.84	-11.68	-59.84%

Attovia Therapeutics, Inc. Corporate Events

Financial DisclosuresPrivate Placements and FinancingProduct-Related Announcements

Attovia Reports Positive Phase 1b Results for ATTO-1310

Positive

Nov 9, 2026

On November 9, 2026, Attovia reported positive topline 12-week Phase 1b results for a single dose of ATTO-1310 in chronic pruritus and high-itch atopic dermatitis. The therapy was generally well tolerated, showed low immunogenicity, suppressed circul...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

Attovia Therapeutics, Inc. AI Stock Analysis